MITF and melanoma: We then used a mass spectrometry approach to interrogate the metabolite profile of the MITF‐high, non‐invasive melanoma cell line IGR37, and the IGR39 cell line derived from the same patient that is MITF‐low, invasive, and exhibits a pseudo‐hypoxic signature (Figure 1e).